Thornburg Investment Management Inc. trimmed its holdings in Avantor, Inc. (NYSE:AVTR – Free Report) by 7.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 461,322 shares of the company’s stock after selling 39,161 shares during the quarter. Thornburg Investment Management Inc. owned 0.07% of Avantor worth $6,209,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently made changes to their positions in the business. Rise Advisors LLC acquired a new stake in Avantor during the first quarter valued at approximately $25,000. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Avantor by 288.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 1,701 shares of the company’s stock valued at $28,000 after buying an additional 1,263 shares in the last quarter. Wealthquest Corp acquired a new stake in shares of Avantor during the 1st quarter valued at $34,000. FNY Investment Advisers LLC bought a new stake in shares of Avantor during the 2nd quarter worth $36,000. Finally, Spire Wealth Management bought a new stake in shares of Avantor during the 2nd quarter worth $47,000. Institutional investors and hedge funds own 95.08% of the company’s stock.
Avantor Stock Performance
Shares of AVTR opened at $11.84 on Wednesday. The company has a market capitalization of $8.07 billion, a PE ratio of -91.10, a PEG ratio of 3.96 and a beta of 1.00. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.96 and a current ratio of 1.49. The company’s 50 day moving average price is $12.78 and its 200 day moving average price is $13.00. Avantor, Inc. has a 52 week low of $10.82 and a 52 week high of $23.32.
Insider Activity
In other news, Director Gregory L. Summe acquired 100,000 shares of Avantor stock in a transaction that occurred on Thursday, October 30th. The stock was purchased at an average price of $11.25 per share, with a total value of $1,125,000.00. Following the completion of the transaction, the director owned 300,000 shares in the company, valued at approximately $3,375,000. This trade represents a 50.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.20% of the company’s stock.
Wall Street Analyst Weigh In
AVTR has been the subject of several analyst reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $12.00 target price (down from $14.00) on shares of Avantor in a report on Thursday, October 30th. Morgan Stanley reduced their price objective on shares of Avantor from $15.00 to $12.00 and set an “equal weight” rating for the company in a research note on Monday, August 4th. Jefferies Financial Group reissued a “hold” rating on shares of Avantor in a research report on Friday, August 1st. Royal Bank Of Canada cut their price target on shares of Avantor from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Monday, August 4th. Finally, Stifel Nicolaus set a $12.00 price target on shares of Avantor and gave the company a “hold” rating in a research report on Monday, August 4th. Four analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Avantor presently has a consensus rating of “Hold” and a consensus price target of $14.42.
Get Our Latest Report on Avantor
About Avantor
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Featured Articles
- Five stocks we like better than Avantor
- What is diluted earnings per share (Diluted EPS)?
- History Says These are 3 Stocks to Buy for December
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
- What is a Stock Market Index and How Do You Use Them?
- From Science Project to Solvent: WeRide’s 761% Revenue Surge
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
